You are here

Mixed Results With RA Drug Fostamatinib in Phase III Trial

Only one of two endpoints met (Apr. 5)

Results have been announced from a phase III study of fostamatinib (AstraZeneca), the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). The OSKIRA-1 trial had two primary endpoints: improvement in the signs and symptoms of RA, as measured by the American College of Rheumatology 20% improvement criteria (ACR20), and the modified Total Sharp Score (mTSS), an X-ray endpoint.

Statistically significant improvements in the ACR20 response rate were achieved at 24 weeks in patients treated with fostamatinib 100 mg twice daily and in patients treated with fostamatinib 100 mg twice daily for 4 weeks followed by 150 mg once daily, both in combination with methotrexate, compared with a group given placebo (49% [P P = 0.006] vs. 34%, respectively).

However, fostamatinib did not demonstrate a statistically significant difference in mTSS compared with placebo at 24 weeks for either dosage (P = 0.252 and P = 0.170, respectively).

The most common adverse events included hypertension, diarrhea, nausea, headache, and nasopharyngitis.

Results from additional fostamatinib trials (OSKIRA-2 and OSKIRA-3) are expected in the second quarter of 2013.

Source: AstraZeneca; April 5, 2013.

Recent Headlines

WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs